Charles River Laboratories International (NYSE:CRL – Get Free Report) and Repligen (NASDAQ:RGEN – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.
Valuation & Earnings
This table compares Charles River Laboratories International and Repligen”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Charles River Laboratories International | $4.00 billion | 3.48 | -$144.34 million | ($4.85) | -60.16 |
| Repligen | $738.26 million | 13.22 | $48.89 million | $0.73 | 236.90 |
Profitability
This table compares Charles River Laboratories International and Repligen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Charles River Laboratories International | -5.96% | 15.75% | 6.51% |
| Repligen | 5.29% | 5.30% | 3.79% |
Volatility & Risk
Charles River Laboratories International has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current recommendations for Charles River Laboratories International and Repligen, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Charles River Laboratories International | 1 | 3 | 12 | 0 | 2.69 |
| Repligen | 0 | 3 | 12 | 3 | 3.00 |
Charles River Laboratories International currently has a consensus target price of $255.65, indicating a potential downside of 12.39%. Repligen has a consensus target price of $166.43, indicating a potential downside of 3.77%. Given Repligen’s stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Charles River Laboratories International.
Insider & Institutional Ownership
98.9% of Charles River Laboratories International shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 1.3% of Charles River Laboratories International shares are held by company insiders. Comparatively, 0.6% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Repligen beats Charles River Laboratories International on 8 of the 14 factors compared between the two stocks.
About Charles River Laboratories International
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
About Repligen
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
